Jamaica Szeliga quoted in Law360

Jamaica Szeliga was quoted in an October 3 story from Law360, "FDA Petition-Shaming Plan Gives Ammo To Antitrust Suits," on how the U.S. Food and Drug Administration appears poised to shame branded-drug makers that make strategically timed objections to generic-drug approval standards, providing new ammunition for antitrust suits over delayed access to lower-cost medicines. Szeliga said that the FDA's imprimatur could be valuable for a case alleging anti-competitive actions.